Co-D Therapeutics

Co-D Therapeutics

Navigation

  • About Co-D
    • Mission & Vision
    • Management
    • Board of Directors
    • Advisory Board
    • Career Opportunities
  • Technology
    • Combination Therapy
  • Pipeline
    • Triolimus
  • Partnering
  • News & Events
    • Co-D in the News
    • Press Releases
    • Events
    • Publications
    • Presentations
  • Contact Us
You are here: Home > Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG
  • August 14, 2012
  • Abdalla Saad

Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG

Categories: Publications

https://www.ncbi.nlm.nih.gov/pubmed/22896668

← Efficacy of Tie2 receptor antagonism in angiosarcoma
Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin →
  • Home
  • About Co-D
  • Technology
  • Pipeline
  • Partnering
  • News & Events
  • Contact Us

Recent Posts

  • Co-D Therapeutics accepted into NCL Laboratory Assay Cascade characterization and testing program
  • Nanoparticles Improve Tumor Treatment in Mice
  • Improving Cancer Diagnosis and Treatment
  • Madison startup advances three-in-one cancer drug rooted at UW
  • Co-D Therapeutics Granted Orphan Designation for Triolimus for the Treatment of Angiosarcoma
Co-D Therapeutics © 2013-2018. All Rights Reserved.                          Home | About Co-D | Technology | Pipeline | Partnering | News & Events | Careers | Contact Us